One of the key comorbidities of type-2-diabetes is non-alcoholic fatty liver disease (NAFLD) – a disease that is increasing worldwide and for which there are no treatment options available today. It can lead to more severe liver damage such as cirrhosis and hepatocellular carcinoma. A group of researchers including the Institute for Diabetes and Cancer at Helmholtz Zentrum München has discovered a potential novel therapeutic target for treating NAFLD: Rab24. The paper is published in Nature Metabolism.
The French members of the team are from C3M at the Université Côte d’Azur.
Read the research paper: Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity. Anja Zeigerer et al. Nature Metabolism